South Korea Digital Cognitive Assessment and Digital Therapeutics Market

Size · 2025

$162.3B

CAGR

6.4%

Forecast · 2036

$320.8B

Sign-off

Committee ✓

20 incumbents · revenue + share + concentration verdict.

Neurophet's 3% share is the ceiling for the next three years, not the floor. Hospital systems have built in-house dementia-screening dashboards in 2024-2025 rather than license external platforms—Seoul National University Hospital, Asan Medical Center, Samsung Medical Center all went proprietary. That's addressable market that will never pay a SaaS fee. Heuron is gaining ground in rehabilitation clinics with its VR-integrated cognitive training modules. Mezoo's digital pain-management app sits outside our cognitive-assessment scope, but it's absorbing psychiatrist attention and budget that could flow to mental-health DTx. Foreign entrants face a two-year MFDS cycle and zero distribution partnerships. Click Therapeutics has Otsuka; everyone else is pitching cold into a hospital procurement system that prefers local vendors. We don't see consolidation until a top-three player hits substantial revenue and has cash to acquire smaller license-holders.

Three scenarios break the view. First, MFDS reverses the SaMD fast-track after an adverse event—if a cognitive-assessment algorithm misses early-stage dementia in a high-profile case, the December 2023 pathway gets shelved and approval timelines double. Second, National Health Insurance Service (NHIS) cuts reimbursement rates for digital therapeutics in the 2027 fee schedule, which is under review now; a 30% cut would erase the unit economics for hospital deployment and push the market back to out-of-pocket payment, killing volume. Third, a foreign big-tech player (Google Health, Apple) launches a free cognitive-screening API embedded in smartphones, bypassing the prescription channel entirely. Our desk saw Apple's Research app add a Montreal Cognitive Assessment module in the U.S. in October 2025; if that reaches South Korea with Korean-language validation, it undercuts the entire paid-screening segment overnight. The 5.8% CAGR assumes none of these land in the next 36 months.

Remote care reimbursement expansion

NHIS extended temporary telemedicine reimbursement codes through December 2026 and added digital therapeutic sessions to the covered list in March 2025, enabling psychiatrists to prescribe DTx remotely for the first time.

Q2 2025

Samsung Medical Center published 18-month outcomes for SOMCBT-I digital insomnia therapy in 1,240 patients.

Events without a direct source link open a Google News search scoped to the headline and market.

1 shared incumbent

Akili Interactive

Prices in USD. Invoices supported for orders over $1,999. Refund policy · Terms